Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.
Intellia’s CEO said that the trial marks the first positive Phase III readout for an in vivo CRISPR gene therapy.
Despite significant advances in orthopedic technology and surgical techniques, infection control in total joint replacements remains an area that has room to grow, surgeons say. The percentage of ...
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and ...
Although recurrent wheezing is a major respiratory disorder among infants and toddlers, standardized protocols have not been ...
Management remit expansion reflecting organization alignment to maximize external engagement and strategy execution COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a ...
Intellia (NTLA) stock dropped 3% despite positive Phase 3 results showing 87% attack reduction. FDA submission underway with ...
Experts said malaria prevention for kids includes using approved repellents, wearing light and long clothing, and staying in ...
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...
Investor's Business Daily on MSN
Intellia successfully edited genes inside the body. Why shares aren't flying
Intellia Therapeutics could soon win Food and Drug Administration approval for the first-ever drug that edits genes inside a ...
Intellia Therapeutics reported that its in vivo CRISPR therapy, lonvo-z, met all primary and secondary endpoints in a Phase 3 ...
Jamaica Broilers is one of the first major Caribbean producers to fully validate antibiotic-free broiler production - learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results